NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Dolutegravir (DTG)
Drug: Placebo for maraviroc (MVC)
Drug: Placebo for dolutegravir (DTG)
Drug: Maraviroc (MVC)

First Posted Date: 2015-08-11

Last Posted Date: 2022-04-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 191

Registration Number: NCT02519777

Locations: 🇺🇸
UCSD Antiviral Research Center CRS, San Diego, California, United States
🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University CRS, Baltimore, Maryland, United States

and more 27 locations

Registry for Asthma Characterization and Recruitment 2

Completed

Conditions: Asthma

First Posted Date: 2015-07-31

Last Posted Date: 2021-01-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1384

Registration Number: NCT02513264

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States

and more 7 locations

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Chloroquine (CQ)
Drug: Pyrimethamine (PYR)
Biological: Sanaria PfSPZ Challenge (NF54)

First Posted Date: 2015-07-29

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT02511054

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation

Phase 1

Terminated

Conditions: PGM3

Interventions: Drug: N-Acetylglucosamine (GlcNAc)
Drug: Uridine

First Posted Date: 2015-07-29

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2

Registration Number: NCT02511041

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge

Conditions: Post Influenza

First Posted Date: 2015-07-29

Last Posted Date: 2025-05-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT02511002

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Other: AP10-602
Biological: GLA-SE
Biological: ID93

First Posted Date: 2015-07-24

Last Posted Date: 2017-09-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT02508376

Locations: 🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States

Natural History and Genetics of Food Allergy and Related Conditions

Recruiting

Conditions: Loeys-Dietz Syndrome
Atopic Dermatitis
Eosinophilic Esophagitis
Food Allergy

First Posted Date: 2015-07-22

Last Posted Date: 2025-03-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1800

Registration Number: NCT02504853

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children

Completed

Conditions: Malaria

First Posted Date: 2015-07-22

Last Posted Date: 2018-06-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT02504918

Locations: 🇲🇱
Ouelessebougou Clinical Research Center MRTC/ FMPOS, Ouelessebougou, Mali

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy

Completed

Conditions: Asthma

First Posted Date: 2015-07-20

Last Posted Date: 2018-02-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 208

Registration Number: NCT02502890

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 6 locations

Magnesium Supplementation in People With XMEN Syndrome

Phase 1

Completed

Conditions: XMEN

Interventions: Dietary Supplement: Magnesium L-threonate
Other: Placebo
Drug: Intravenous (IV) magnesium sulfate (MgSO4)

First Posted Date: 2015-07-14

Last Posted Date: 2022-03-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT02496676

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy